RICH PHARMACEUTICALS, INC. (OTCMKTS:RCHA) Files An 8-K Unregistered Sales of Equity SecuritiesItem 3.02
On April 4, 2018 the Company issued 85,280,000 shares of Company common stock to satisfy the conversion of $8,528.00 of a convertible note payable with GHS Investments, LLC.
On April 10, 2018 the Company issued 89,530,000 shares of Company common stock to satisfy the conversion of $8,953.00 of a convertible note payable with GHS Investments, LLC.
The above-referenced issuances of shares were made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering. The Company's reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only a one investor who was an accredited investor; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the issuance of shares was to a convertible note payable which was negotiated directly between the investor and the Company.
The total number of outstanding shares of common stock of the Company as of April 13, 2018 after the above described issuances is 1,883,867,821.
About RICH PHARMACEUTICALS, INC. (OTCMKTS:RCHA)
Rich Pharmaceuticals, Inc. is a development-stage company. The Company is a biopharmaceutical company focused on developing and commercializing therapies in oncology. The Company is developing 12-O-tetradecanoylphorbol-13-acetate (RP-323) for the treatment of Hodgkin’s lymphoma (HL), Acute Myelogenous Leukemia (AML) and to cause elevation of white blood cells in patients depleted of these elements due to various conditions. RP-323 is a naturally occurring compound. RP-323 converts cancer cells to normal cells, a process called differentiation. It is also observed in some instances to cause cancer cell death. Clinical studies in over 100 cancer patients demonstrated the ability of RP-323 to stimulate the production of white blood cells and neutrophils. The Company has no products ready for commercialization. The Company had no revenues during the period ending March 31, 2016.
